人民财讯8月13日电，华大基因（300676）8月13日晚间公告，公司持股8.24%的股东深圳生华投资企业 (有限合伙)(简称"生华投资")，计划15个交易日后的3个月内，通过集中竞价、大宗交易方式，减持公司 股份不超过627.48万股，即不超过公司总股本的1.5%。 ...

华大基因公告，持股5%以上股东深圳生华投资企业（有限合伙）现持股3447.05万股，占8.2403%，计 划于2025年9月4日—2025年12月3日，通过集中竞价、大宗交易方式减持不超过627.48万股，即不超过 1.5000%。减持股份来源为公司首次公开发行前已持有股份，减持价格不低于首次公开发行时的发行价 格。 ...

深圳华大基因股份有限公司 关于持股 5%以上股东减持股份计划的预披露公告 持股 5%以上的股东深圳生华投资企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 证券代码：300676 证券简称：华大基因 公告编号：2025-041 深圳华大基因股份有限公司（以下简称公司或上市公司）持股 5%以上股东深 圳生华投资企业（有限合伙）（以下简称生华投资）持有公司股份 34,470,455 股， 占公司总股本 418,317,075 股的 8.2403%。生华投资计划自本减持计划公告之日起 15 个交易日后的 3 个月内（2025 年 9 月 4 日—2025 年 12 月 3 日），通过集中竞 价、大宗交易方式减持公司股份不超过 6,274,756 股（即不超过公司总股本比例的 1.5000%）。 公司近日收到持股 5%以上的股东生华投资出具的《股份减持计划的告知函》， 现将有关情况公告如下： 一、股东的基本情况 （一） 股东名称 深圳生华投资企业（有限合伙） （二） 股东持股情况 | 深圳 ...

融券方面，当日融券卖出0.00万股，净买入0.05万股。 8月11日，沪深两融数据显示，华大基因获融资买入额0.39亿元，居两市第1197位，当日融资偿还额0.59 亿元，净卖出1994.48万元。 最近三个交易日，7日-11日，华大基因分别获融资买入0.93亿元、0.83亿元、0.39亿元。 ...

Group 1 - The core viewpoint of the article highlights the financial performance and market activity of BGI Genomics Co., Ltd. as of August 11, 2025, showing a decline in revenue and net profit compared to the previous year [1] - As of the latest quarterly report, the company reported total revenue of 672 million yuan, a year-on-year decrease of 18.18%, and a net profit attributable to shareholders of 52.6951 million yuan, down 524.87% [1] - The company's liquidity ratios are strong, with a current ratio of 2.854 and a quick ratio of 2.617, while the debt-to-asset ratio stands at 26.68% [1] Group 2 - BGI Genomics has made investments in 71 companies and participated in 42 bidding projects, indicating active engagement in business expansion [2] - The company holds a significant intellectual property portfolio, with 665 trademark registrations and 375 patents, along with 14 administrative licenses [2]

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...

Core Viewpoint - A case in the A-share market highlights the integration of health benefits into shareholder rewards, showcasing the effectiveness of the company's technology in a real-life scenario [1] Group 1: Company Initiatives - BGI Genomics (华大基因) launched a shareholder reward program in February 2025, allowing shareholders who have held shares for over a year to receive a free health screening kit [1] - The company emphasizes the importance of health as part of its shareholder return system, enabling shareholders to experience the benefits of its technology firsthand [1] Group 2: Case Study - A 35-year-old shareholder participated in the annual shareholder reward activity and received a health screening, which led to the early detection of a tumor through a colonoscopy [1] - The shareholder had purchased BGI Genomics stock in July 2022 and underwent surgery in early July 2023, with a good recovery reported [1]

Core Insights - The article highlights a significant case where a shareholder of BGI Genomics, Mr. Han, credits the company's health screening service with saving his life by detecting early-stage cancer through a free genetic test [2][8]. Group 1: Company Initiatives - BGI Genomics launched the "2025 Annual Shareholder Return Activity," allowing long-term shareholders to receive free health screenings, which reflects the company's commitment to shareholder welfare and health [3][8]. - The company emphasizes its mission of "genetic technology benefiting humanity," aiming to improve public health and quality of life through the application of life sciences [9]. Group 2: Health Screening Impact - Mr. Han's experience illustrates the effectiveness of BGI's fecal DNA methylation testing, which can detect early signs of colorectal cancer, highlighting the importance of early screening in preventing severe health issues [10][12]. - The article notes that colorectal cancer is the second most common cancer in China, with a rising incidence among younger populations, underscoring the need for increased awareness and screening [10][12]. Group 3: Industry Context - The article discusses the challenges in colorectal cancer screening, including the low screening rates due to the invasive nature of traditional methods, and advocates for non-invasive tests like BGI's as a viable alternative [12]. - It emphasizes the importance of proactive health management, encouraging individuals to take charge of their health rather than waiting for symptoms to appear [12].

Group 1 - The core message highlights the successful early detection of colorectal cancer through the company's product, 华常康®, which saved a shareholder's life [2][3] - The company initiated a shareholder reward program in February 2023, providing health screening products to shareholders, which demonstrates its commitment to health and wellness [2][3] - Colorectal cancer is the second most common cancer in China, with a rising incidence among younger populations, emphasizing the need for early screening [2] Group 2 - The 华常康® product utilizes non-invasive fecal DNA methylation testing to assess cancer risk, addressing low screening rates due to the invasive nature of traditional methods [3] - The company has integrated health into its shareholder return system, allowing shareholders to experience the effectiveness and long-term value of its technology firsthand [3] - This initiative reflects the company's mission of using genetic technology to benefit humanity [3]

Group 1 - The core viewpoint of the news highlights the successful early detection of colorectal cancer through the non-invasive Hua Chang Kang testing product by BGI Genomics, demonstrating its significant value in early diagnosis [1] - A shareholder, Mr. Han, participated in the company's annual shareholder reward activity and received the Hua Chang Kang intestinal health testing product, which led to the early detection of his colorectal cancer [1] - The testing revealed three positive gene methylation results, prompting further examination that confirmed the presence of a tumor, which was successfully surgically removed [1] Group 2 - According to the National Cancer Center's 2024 data, colorectal cancer is the second most common cancer in China, with a rising incidence in urban areas and a concerning trend of younger patients [2] - The "Guidelines for Colorectal Cancer Screening and Early Diagnosis and Treatment (2020)" recommend early screening for high-risk groups, including those with a family history of colorectal cancer, previous polyps, or chronic intestinal diseases [2] - BGI Genomics' Hua Chang Kang product utilizes fecal DNA methylation testing to analyze specific gene changes, providing a sensitive and specific method for detecting precancerous lesions or early cancer signals [2]